https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-first-case-stable-disease-three-months-ovarian BiopharmaWatch en 2026-10-05T12:15:00.000Z Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial https://www.biopharmawatch.com/news/ARDX/ardelyx-new-data-hyperphosphatemia-asn-kidney-week-2026 BiopharmaWatch en 2026-10-05T12:01:00.000Z Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/PCRX/pacira-molteni-agreement-exparel-eu-uk BiopharmaWatch en 2026-10-05T12:00:03.000Z Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom https://www.biopharmawatch.com/news/RANI/rani-therapeutics-fda-emerging-technology-program BiopharmaWatch en 2026-10-05T12:00:01.000Z Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) https://www.biopharmawatch.com/news/ESTA/establishment-labs-receives-fda-approval-additional-sizes-motiva-implants BiopharmaWatch en 2026-10-05T12:00:00.000Z Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants® https://www.biopharmawatch.com/news/ELV/elevance-health-conference-call-q3-2026-results BiopharmaWatch en 2026-10-05T12:00:00.000Z Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026 https://www.biopharmawatch.com/news/BFLY/butterfly-network-appoints-mike-noonen-board BiopharmaWatch en 2026-10-05T12:00:00.000Z Butterfly Network Appoints Mike Noonen to Board of Directors https://www.biopharmawatch.com/news/COYA/coya-therapeutics-phase-2-3-alstars-trial-completion BiopharmaWatch en 2026-10-05T12:00:00.000Z Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS https://www.biopharmawatch.com/news/GEHC/ge-healthcare-acquire-sofie-biosciences-pet-radiopharmaceuticals BiopharmaWatch en 2026-10-05T12:00:00.000Z GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S. https://www.biopharmawatch.com/news/NTRA/aft-70-navigate-global-randomized-phase-iii-trial BiopharmaWatch en 2026-10-05T12:00:00.000Z Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer https://www.biopharmawatch.com/news/ICU/seastar-medical-warrant-exercise-3-3-million BiopharmaWatch en 2026-10-05T12:00:00.000Z SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds https://www.biopharmawatch.com/news/FDMT/4dmt-investor-day-october-2026 BiopharmaWatch en 2026-10-05T12:00:00.000Z 4DMT to Host Investor Day on October 21, 2026 https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-appoints-matt-eckler-board BiopharmaWatch en 2026-10-05T12:00:00.000Z PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors https://www.biopharmawatch.com/news/CELC/celcuity-esmo-congress-2026-presentations BiopharmaWatch en 2026-10-05T12:00:00.000Z Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/LSTA/marea-therapeutics-phase-2-trial-mar002-acromegaly BiopharmaWatch en 2026-10-05T12:00:00.000Z Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-phase-3-catt1-study-completion BiopharmaWatch en 2026-10-05T12:00:00.000Z vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) https://www.biopharmawatch.com/news/TELA/tela-bio-510k-clearance-liora-scaffold BiopharmaWatch en 2026-10-05T12:00:00.000Z TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement https://www.biopharmawatch.com/news/HIND/vyome-usp-to-notice-allowance-vt-1908-patent BiopharmaWatch en 2026-10-05T12:00:00.000Z Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market https://www.biopharmawatch.com/news/PRME/prime-medicine-phase-1-2-trial-pm577a-wilson-disease BiopharmaWatch en 2026-10-05T11:59:59.000Z Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease https://www.biopharmawatch.com/news/LLY/lilly-dermatology-data-fall-clinical-2026 BiopharmaWatch en 2026-10-05T11:50:00.000Z Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-us-patent-dor-technology BiopharmaWatch en 2026-10-05T11:45:00.000Z TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology https://www.biopharmawatch.com/news/PLRZ/polyrizon-files-us-patent-intranasal-drug-delivery BiopharmaWatch en 2026-10-05T11:32:00.000Z Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform https://www.biopharmawatch.com/news/BBIO/bbp-418-potential-disease-modifying-therapy-lgmd2i-r9 BiopharmaWatch en 2026-10-05T11:30:00.000Z BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels https://www.biopharmawatch.com/news/BLCO/bausch-lomb-third-quarter-2026-results BiopharmaWatch en 2026-10-05T11:30:00.000Z Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-fda-clearance-ind-cr-002 BiopharmaWatch en 2026-10-05T11:30:00.000Z Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors https://www.biopharmawatch.com/news/MMED/minimed-smart-mdi-alerts-glucose-outcomes BiopharmaWatch en 2026-10-05T11:08:00.000Z Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes https://www.biopharmawatch.com/news/HLF/herbalife-maxim-growth-summit-october-14 BiopharmaWatch en 2026-10-05T11:05:00.000Z Herbalife to Participate in 1 on 1 Meetings at Maxim Growth Summit on October 14 https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ath434-phase-2-data-multiple-system-atrophy BiopharmaWatch en 2026-10-05T11:05:00.000Z Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders https://www.biopharmawatch.com/news/IVVD/invivyd-inducement-grants-nasdaq-listing-rule BiopharmaWatch en 2026-10-05T11:01:00.000Z Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PBM/psyence-biomeds-ibogaine-manufacturing-partnership BiopharmaWatch en 2026-10-05T11:00:00.000Z Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine https://www.biopharmawatch.com/news/ALEC/alector-genentech-license-agreement-parkinsons-disease BiopharmaWatch en 2026-10-05T11:00:00.000Z Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases https://www.biopharmawatch.com/news/MSLE/satellos-granted-patent-for-forazapadin BiopharmaWatch en 2026-10-05T11:00:00.000Z Satellos Granted Composition of Matter Patent for Forazapadin https://www.biopharmawatch.com/news/BCRX/biocryst-scientific-advisory-board-formation BiopharmaWatch en 2026-10-05T11:00:00.000Z BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth https://www.biopharmawatch.com/news/SMMT/astrazeneca-completes-2-billion-investment-summit-therapeutics BiopharmaWatch en 2026-10-05T11:00:00.000Z AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-fda-meeting-zorevunersen-dravet-syndrome BiopharmaWatch en 2026-10-05T11:00:00.000Z Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome https://www.biopharmawatch.com/news/IRIX/iridex-relocation-manufacturing-facility-san-jose BiopharmaWatch en 2026-10-05T11:00:00.000Z Iridex Completes Relocation of Manufacturing Facility to San Jose, California https://www.biopharmawatch.com/news/RZLT/rezolute-fda-pre-bla-meeting-ersodetug BiopharmaWatch en 2026-10-05T11:00:00.000Z Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism https://www.biopharmawatch.com/news/HROW/harrow-acquires-tyrvaya-nasal-spray BiopharmaWatch en 2026-10-05T11:00:00.000Z Harrow Closes Acquisition of TYRVAYA® https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-research-term-extension-gilead BiopharmaWatch en 2026-10-05T11:00:00.000Z Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences https://www.biopharmawatch.com/news/VTRS/viatris-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-05T10:59:00.000Z Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/PHVS/real-world-analysis-hai-disease-experience-treatment-gaps BiopharmaWatch en 2026-10-05T10:50:27.000Z Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy https://www.biopharmawatch.com/news/CMPS/compass-pathways-new-office-jersey-city BiopharmaWatch en 2026-10-05T10:30:00.000Z Compass Pathways Celebrates Opening of New U.S. Office in Jersey City, New Jersey https://www.biopharmawatch.com/news/FTRE/fortrea-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-05T10:30:00.000Z Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call https://www.biopharmawatch.com/news/EW/edwards-lifesciences-host-investor-event-tct BiopharmaWatch en 2026-10-05T10:00:00.000Z Edwards Lifesciences to Host Investor Event in Conjunction With TCT https://www.biopharmawatch.com/news/WST/west-highlight-industry-leadership-cphi-worldwide BiopharmaWatch en 2026-10-05T10:00:00.000Z West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-1-phase-3-trial-results BiopharmaWatch en 2026-10-05T10:00:00.000Z Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate https://www.biopharmawatch.com/news/ALVO/fda-approves-additional-manufacturing-capacity-simlandi BiopharmaWatch en 2026-10-05T08:00:00.000Z FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® https://www.biopharmawatch.com/news/BMY/help-save-a-life-blood-donation-drive-bmy BiopharmaWatch en 2026-10-05T07:54:00.000Z Driving Community Health: Bristol Myers Squibb, Emirates Thalassemia Society and Dubai Science Park Host the 6th 'Help Save a Life' Blood Donation Drive https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-05 BiopharmaWatch en 2026-10-05T07:15:33.007Z SIL204 Phase 2/3 for Locally Advanced Pancreatic Cancer: Biotech Catalysts Oct 5, 2026 https://www.biopharmawatch.com/news/PCVX/vaxcyte-webcast-opus-1-phase-3-trial-data BiopharmaWatch en 2026-10-04T21:00:00.000Z Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-ovarian-cancer-bot-bal BiopharmaWatch en 2026-10-04T02:42:00.000Z Agenus informa una supervivencia estimada a tres años del 48 % con BOT+BAL para cáncer de ovarios recurrente en IGCS 2026 https://www.biopharmawatch.com/news/AGEN/riassunto-agenus-segnala-una-sopravvivenza-tre-anni-stimata-al-48 BiopharmaWatch en 2026-10-04T02:42:00.000Z Riassunto: Agenus segnala una sopravvivenza a tre anni stimata al 48% con BOT+BAL nel tumore ovarico recidivante all'IGCS 2026 https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-rate-ovarian-cancer BiopharmaWatch en 2026-10-04T02:41:00.000Z Samenvatting: Agenus rapporteert een geschatte driejarige overleving van 48% met BOT+BAL bij recidiverende eierstokkanker tijdens IGCS 2026 https://www.biopharmawatch.com/news/AGEN/agenus-dreijahresueberlebensrate-eierstockkrebs BiopharmaWatch en 2026-10-04T02:40:00.000Z Agenus meldet auf der IGCS 2026 eine geschätzte Dreijahresüberlebensrate von 48 % mit BOT+BAL bei rezidivierendem Eierstockkrebs https://www.biopharmawatch.com/news/GMAB/genmab-rinatabart-sesutecan-phase-2-results-ovarian-cancer BiopharmaWatch en 2026-10-03T19:40:00.000Z Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-bot-bal-ovarian-cancer BiopharmaWatch en 2026-10-03T14:50:00.000Z Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026